Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
folate-appended methyl-beta-cyclodextrin
- Development stage
- Preclinical
- Lead developer
- Kumamoto University
- Modality
- Small Molecules
- Administration
- Intravenous, Intratumoral
01
Overview
Folate-appended methyl-beta-cyclodextrin (FA-M-beta-CyD) is a targeted anticancer research compound developed by investigators at Kumamoto University. It consists of a methyl-beta-cyclodextrin (M-beta-CyD) core conjugated with folic acid to provide selectivity for cells overexpressing the folate receptor (FR), particularly folate receptor-alpha (FR-alpha). The compound functions by binding to FR-alpha on the surface of tumor cells, leading to its internalization. Once inside the cell, it induces autophagy-mediated cell death and mitophagy. Preclinical studies in mouse models have demonstrated that FA-M-beta-CyD significantly inhibits tumor growth in FR-positive malignancies, including colorectal, ovarian, and lung cancers, with efficacy comparable or superior to conventional chemotherapeutic agents like doxorubicin.
- Other names
- folate-conjugated methyl-beta-cyclodextrinfolate-appended M-beta-CyD
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on folate-appended methyl-beta-cyclodextrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on folate-appended methyl-beta-cyclodextrin.